Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

1.

Evaluation of 3,3'-diindolylmethane with gardasil quadrivalent HPV vaccine in K14-HPV16-transgenic mice cervical histology.

Sepkovic DW, Pagan DV, Stein J, Carlisle AD, Ksieski HB, Auborn K, Nyirenda T, Bradlow HL.

In Vivo. 2013 May-Jun;27(3):299-304.

PMID:
23606684
[PubMed - indexed for MEDLINE]
2.

3,3'-Diindolylmethane increases serum interferon-γ levels in the K14-HPV16 transgenic mouse model for cervical cancer.

Sepkovic DW, Raucci L, Stein J, Carlisle AD, Auborn K, Ksieski HB, Nyirenda T, Bradlow HL.

In Vivo. 2012 Mar-Apr;26(2):207-11.

PMID:
22351660
[PubMed - indexed for MEDLINE]
3.

Results from a dose-response study using 3,3'-diindolylmethane in the K14-HPV16 transgenic mouse model: cervical histology.

Sepkovic DW, Stein J, Carlisle AD, Ksieski HB, Auborn K, Raucci L, Nyirenda T, Bradlow HL.

Cancer Prev Res (Phila). 2011 Jun;4(6):890-6. doi: 10.1158/1940-6207.CAPR-10-0369. Epub 2011 Mar 7.

PMID:
21383027
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Diindolylmethane inhibits cervical dysplasia, alters estrogen metabolism, and enhances immune response in the K14-HPV16 transgenic mouse model.

Sepkovic DW, Stein J, Carlisle AD, Ksieski HB, Auborn K, Bradlow HL.

Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2957-64. doi: 10.1158/1055-9965.EPI-09-0698. Epub 2009 Oct 27. Erratum in: Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):628.

PMID:
19861518
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).

Kaufmann AM, Nieland JD, Jochmus I, Baur S, Friese K, Gabelsberger J, Gieseking F, Gissmann L, Glasschröder B, Grubert T, Hillemanns P, Höpfl R, Ikenberg H, Schwarz J, Karrasch M, Knoll A, Küppers V, Lechmann M, Lelle RJ, Meissner H, Müller RT, Pawlita M, Petry KU, Pilch H, Walek E, Schneider A.

Int J Cancer. 2007 Dec 15;121(12):2794-800.

PMID:
17721997
[PubMed - indexed for MEDLINE]
6.

Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.

Capri S, Gasparini R, Panatto D, Demarteau N.

Gynecol Oncol. 2011 Jun 1;121(3):514-21. doi: 10.1016/j.ygyno.2011.01.029. Epub 2011 Feb 19.

PMID:
21334734
[PubMed - indexed for MEDLINE]
7.
8.

The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening.

Sigurdsson K, Sigvaldason H, Gudmundsdottir T, Sigurdsson R, Briem H.

Acta Obstet Gynecol Scand. 2009;88(1):27-35. doi: 10.1080/00016340802566770.

PMID:
19031282
[PubMed - indexed for MEDLINE]
9.

Oral diindolylmethane (DIM): pilot evaluation of a nonsurgical treatment for cervical dysplasia.

Del Priore G, Gudipudi DK, Montemarano N, Restivo AM, Malanowska-Stega J, Arslan AA.

Gynecol Oncol. 2010 Mar;116(3):464-7. doi: 10.1016/j.ygyno.2009.10.060. Epub 2009 Nov 24.

PMID:
19939441
[PubMed - indexed for MEDLINE]
10.

Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.

Demarteau N, Tang CH, Chen HC, Chen CJ, Van Kriekinge G.

Value Health. 2012 Jul-Aug;15(5):622-31. doi: 10.1016/j.jval.2012.02.012. Epub 2012 Jun 12.

PMID:
22867770
[PubMed - indexed for MEDLINE]
11.

[Diseases caused by human papilloma viruses].

Zollner U, Schwarz TF.

Dtsch Med Wochenschr. 2011 May;136(20):1067-72. doi: 10.1055/s-0031-1275845. Epub 2011 May 10. Review. German.

PMID:
21560109
[PubMed - indexed for MEDLINE]
12.

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?

Kang WD, Choi HS, Kim SM.

Gynecol Oncol. 2013 Aug;130(2):264-8. doi: 10.1016/j.ygyno.2013.04.050. Epub 2013 Apr 26.

PMID:
23623831
[PubMed - indexed for MEDLINE]
Free Article
13.

Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial.

Castañon A, Tristram A, Mesher D, Powell N, Beer H, Ashman S, Rieck G, Fielder H, Fiander A, Sasieni P.

Br J Cancer. 2012 Jan 3;106(1):45-52. doi: 10.1038/bjc.2011.496. Epub 2011 Nov 10.

PMID:
22075942
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.

Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Maansson R, Lu S, Vuocolo S, Hesley TM, Saah A, Barr E, Haupt RM.

Cancer Prev Res (Phila). 2009 Oct;2(10):868-78. doi: 10.1158/1940-6207.CAPR-09-0031. Epub 2009 Sep 29.

PMID:
19789295
[PubMed - indexed for MEDLINE]
15.

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.

J Natl Cancer Inst. 2010 Mar 3;102(5):325-39. doi: 10.1093/jnci/djp534. Epub 2010 Feb 5.

PMID:
20139221
[PubMed - indexed for MEDLINE]
Free Article
16.

Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.

Van de Velde N, Boily MC, Drolet M, Franco EL, Mayrand MH, Kliewer EV, Coutlée F, Laprise JF, Malagón T, Brisson M.

J Natl Cancer Inst. 2012 Nov 21;104(22):1712-23. doi: 10.1093/jnci/djs395. Epub 2012 Oct 27.

PMID:
23104323
[PubMed - indexed for MEDLINE]
Free Article
17.

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.

Castellsagué X, Schneider A, Kaufmann AM, Bosch FX.

Gynecol Oncol. 2009 Dec;115(3 Suppl):S15-23. doi: 10.1016/j.ygyno.2009.09.021. Epub 2009 Oct 12.

PMID:
19819540
[PubMed - indexed for MEDLINE]
18.

Age-appropriate use of human papillomavirus vaccines in the U.S.

Castle PE, Fetterman B, Akhtar I, Husain M, Gold MA, Guido R, Glass AG, Kinney W.

Gynecol Oncol. 2009 Aug;114(2):365-9. doi: 10.1016/j.ygyno.2009.04.035. Epub 2009 May 22. Review.

PMID:
19464729
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Spotlight on AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®).

McKeage K, Romanowski B.

BioDrugs. 2011 Aug 1;25(4):265-9. doi: 10.2165/11206830-000000000-00000.

PMID:
21815703
[PubMed - indexed for MEDLINE]
20.

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.

FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R.

BMJ. 2010 Jul 20;341:c3493. doi: 10.1136/bmj.c3493.

PMID:
20647284
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk